FDA frustration

Back in April the FDA had the opportunity to approve use of a parp inhibitor, a new class of drugs, for sale in the US but for a limited use regarding ovarian cancer.  They declined.  Next week the EU will likely approve the same drug for broad use in treating this disease.  While we wait 1200 women per month die in the US. , 40 women per day.  With avastin it took the US 4 years to approve it for ovarian cancer treatment, while the EU was using it.  thousands died waiting.  Something is severely wrong with this picture.  The parp will not cure us but keep us alive longer until the next drug is approved and the next drug while we find the drug that will keep us in equipoise with this disease, even if there is no cure.